Valproate (Epilepsy)

Gestational diabetes

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S8087
R24747		 Aydin (Valproate) (Controls exposed to Lamotrigine, sick), 2020 Gestational diabetes mellitus throughout pregnancy retrospective cohort exposed to other treatment, sick excluded Adjustment: No 0.62 [0.01;35.19] C
excluded (control group) 		0/11   0/7 0 11
ref
S7922
R24624		 Aydin (Valproate) (Controls unexposed, sick), 2020 Gestational diabetes mellitus throughout pregnancy retrospective cohort unexposed, sick Adjustment: No 0.65 [0.02;17.40] C 0/11   1/22 1 11
ref
S6416
R17614		 Pennell (Valproate), 2012 Gestational Diabetes during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick Adjustment: No 0.31 [0.03;2.69] C 1/61   5/97 6 61
ref
S7231
R20842		 McVearry (Valproate), 2009 Gestational diabetes during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick Adjustment: No 2.13 [0.12;38.48] C 1/9   1/18 2 9
ref
Total 3 studies 0.62 [0.13;2.89] 9 81
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Aydin (Valproate) (Controls unexposed, sick), 2020Aydin, 2020 1 0.65[0.02; 17.40]11122%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Pennell (Valproate), 2012Pennell, 2012 2 0.31[0.03; 2.69]66150%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA McVearry (Valproate), 2009McVearry, 2009 3 2.13[0.12; 38.48]2928%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 0% 0.62[0.13; 2.89]9810.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Valproate) (Controls unexposed, sick; 2: Valproate; 3: Valproate;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.62[0.13; 2.89]9810%NAAydin (Valproate) (Controls unexposed, sick), 2020 Pennell (Valproate), 2012 McVearry (Valproate), 2009 3 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.65[0.02; 17.40]111 -NAAydin (Valproate) (Controls unexposed, sick), 2020 1 exposed to other treatment, sickexposed to other treatment, sick 0.63[0.10; 3.95]8709%NAPennell (Valproate), 2012 McVearry (Valproate), 2009 2 Tags Adjustment   - No  - No 0.62[0.13; 2.89]9810%NAAydin (Valproate) (Controls unexposed, sick), 2020 Pennell (Valproate), 2012 McVearry (Valproate), 2009 3 All studiesAll studies 0.62[0.13; 2.89]9810%NAAydin (Valproate) (Controls unexposed, sick), 2020 Pennell (Valproate), 2012 McVearry (Valproate), 2009 30.15.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 8087

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 0.65[0.02; 17.40]111 -NAAydin (Valproate) (Controls unexposed, sick), 2020 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.62[0.12; 3.04]8810%NAAydin (Valproate) (Controls exposed to Lamotrigine, sick), 2020 Pennell (Valproate), 2012 McVearry (Valproate), 2009 30.510.01.0